Business
Currency:USD
2024/Q1
Stock NameRevenueRatio
TYSABRI431.3M18.83%
Revenue from anti-CD20 therapeutic programs394M17.20%
SPINRAZA341.3M14.90%
TECFIDERA254.3M11.10%
Contract manufacturing, royalty and other revenue184.6M8.06%
Other182.3M7.96%
AVONEX178.5M7.79%
VUMERITY127.5M5.57%
BENEPALI118.7M5.18%
SKYCLARYS78M3.41%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
U.S.5.43B55.24%
Europe2.14B21.75%
Germany868M8.83%
Asia863.4M8.78%
Other531.2M5.40%
